ClinicalTrials.gg
RecruitingNCT07407933Updated Sep 17, 2026

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of YL201 and Atezolizumab in Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Primary conditionSmall Cell Lung CarcinomaRegistry: Thoracic NeoplasmsReclassifiedWhy we changed it
Registry
Thoracic Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Small Cell Lung Carcinoma
Why
  1. The study's listed conditions name Small Cell Lung Carcinoma, a narrower term within Thoracic Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Small Cell Lung Carcinoma with a site in Spain — 38 open to participants now, 65 under way, 23 of them phase 3. Small Cell Lung Carcinoma · Spain.

Planned enrollment
89th of 135
118 · median 184
Started
2026
with 14 others
Phase 1/2
26 of 141
13 open now
Primary completion
2028-11
later than 41 of 64 live
Registered
132nd of 141
by date

Among the 141 studies in Small Cell Lung Carcinoma with a site in Spain, this one is the 89th largest by planned enrollment of the 135 interventional ones that give a count, is one of 15 that started in 2026, is one of 26 in phase 1/2, reaches primary completion later than 41 of the 64 other live ones, and was the 132nd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

38 of the 141 studies in Small Cell Lung Carcinoma with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Small Cell Lung Carcinoma with a site in Spain, or all of them as a file.
02

Study summary

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.

03

Conditions studied

  • Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma

Browse trials for

Keywords

  • Small cell lung cancer, Antibody drug conjugate, YL201, atezolizumab
04

In context

Small Cell Lung Carcinoma Reclassified

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

This study's planned enrollment of 118 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.

Browse Small Cell Lung Carcinoma studies →

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Compared within Small Cell Lung Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thoracic Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.18 years of age or older. 2. or cytologically confirmed diagnosis of ES-SCLC 3. performance status of 0 or 1 4. Adequate hematologic and end-organ function

Exclusion criteria

Exclusion Criteria:

  1. No prior systemic anti-cancer treatment for ES-SCLC
  2. No prior treatment targeting B7H3 or topoisomerase I inhibitor
  3. No clinically active or spinal cord compression
  4. No current or history of interstitial lung disease (ILD)/ pneumonitis
  5. No cardiovascular disease (eg, class II to IV congestive heart failure)

Other protocol-defined inclusion/ exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    YL201 1.2mg/kg in combination with atezolizumab 1200mg Q3W

    Drug: YL201 · Drug: Atezolizumab

  • Experimental
    YL201 1.6mg/kg in combination with atezolizumab 1200mg Q3W

    Drug: YL201 · Drug: Atezolizumab

  • Experimental
    YL201 2.0mg/kg in combination with atezolizumab 1200mg Q3W

    Drug: YL201 · Drug: Atezolizumab

Interventions

  • DrugYL201

    YL201 intravenous infusion will be administered on Day 1 of each 21-day cycle.

  • Atezolizumab intravenous infusion will be administered at a dose of 1200 mg on Day 1 of each 21-day cycle

07

What researchers measure

Primary outcomes

  1. Nature and Frequency with Dose-Limiting Toxicities (DLTs)

    Time frame: 21 days

  2. Adverse Events

    Incidence, nature, and severity of AEs graded according to the NCI CTCAE v5

    Time frame: First dose of study treatment up to disease progression or death from any cause (up to approximately 6 years)

Secondary outcomes

  1. ORR

    Time frame: Up to approximately 3 years

  2. DOR

    Time frame: Up to approximately 3 years

  3. PFS

    Time frame: Up to approximately 3 years

  4. OS

    Time frame: Up to approximately 3 years

  5. AUC

    Time frame: Up to approximately 3 years

  6. CL

    Time frame: Up to approximately 3 years

  7. Vss

    Time frame: Up to approximately 3 years

  8. t1/2

    Time frame: Up to approximately 3 years

  9. Cmax

    Time frame: Up to approximately 3 years

08

Study locations

38 of 38 sites recruiting
  • Site 1001
    Washington D.C., District of Columbia 20057, United States
    Recruiting
    • Study Coordinator · Contact
  • Site 1009
    Plantation, Florida 33322, United States
    Recruiting
    • Study Coordinator · Contact
  • Site 1004
    Louisville, Kentucky 40202, United States
    Recruiting
    • Study Coordinator · Contact
  • Site 1005
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact
  • Site 1002
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact
  • Site 1203
    Edegem, 2650, Belgium
    Recruiting
    • Study Coordinator · Contact
  • Site 1201
    Namur, 5000, Belgium
    Recruiting
    • Study Coordinator · Contact
  • Site 1402
    Nice, 06189, France
    Recruiting
    • Study Coordinator · Contact
  • Site 1404
    Paris, 92210, France
    Recruiting
    • Study Coordinator · Contact
  • Site 1403
    Suresnes, 92150, France
    Recruiting
    • Study Coordinator · Contact
  • Site 1601
    Kalocsa, 6300, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Site 1705
    Candiolo, 10060, Italy
    Recruiting
    • Study Coordinator · Contact
  • Site 1703
    Meldola, 47014, Italy
    Recruiting
    • Study Coordinator · Contact
  • Site 1702
    Ravenna, 48121, Italy
    Recruiting
    • Study Coordinator · Contact
  • Site 1802
    Otwock, 05-400, Poland
    Recruiting
    • Study Coordinator · Contact
  • Site 1804
    Poznan, 60-569, Poland
    Recruiting
    • Study Coordinator · Contact
  • Site 1801
    Przemyśl, 37-700, Poland
    Recruiting
    • Study Coordinator · Contact
  • Site 1904
    Bucharest, 022328, Romania
    Recruiting
    • Study Coordinator · Contact
  • Site 1903
    Cluj-Napoca, 400015, Romania
    Recruiting
    • Study Coordinator · Contact
  • Site 1901
    Craiova, 109, Romania
    Recruiting
    • Study Coordinator · Contact
  • Site 2013
    Badajoz, 06080, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2012
    Badalona, 08916, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2014
    Barcelona, 08017, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2003
    Barcelona, 08023, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2006
    Barcelona, 08028, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2001
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2007
    Girona, 17007, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2002
    Madrid, 28034, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2005
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2019
    Madrid, 28050, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2004
    Madrid, 28223, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2011
    Madrid, 28850, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2010
    Manresa, 08242, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2008
    Seville, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2009
    Valencia, 46010, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2015
    Valencia, 46026, Spain
    Recruiting
    • Study Coordinator · Contact
  • Site 2203
    Edinburgh, EH4 2XU, United Kingdom
    Recruiting
    • Study Coordinator · Contact
  • Site 2201
    London, W12 0HS, United Kingdom
    Recruiting
    • Study Coordinator · Contact
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2028, 32 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 32 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 12, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Feb 2029
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07407933
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Mar 31, 2026
Primary completion
Nov 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Sep 17, 2026

Study contacts

MediLink Study Team
Contact
clinicaltrials@medilinkthera.com
86 0512-62858368

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tambotatug pelitecan

Start the discussion